NM_002528.7(NTHL1):c.310C>A (p.His104Asn) AND Hereditary cancer-predisposing syndrome

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Oct 30, 2021
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV002320964.2

Allele description [Variation Report for NM_002528.7(NTHL1):c.310C>A (p.His104Asn)]

NM_002528.7(NTHL1):c.310C>A (p.His104Asn)

Gene:

NTHL1:nth like DNA glycosylase 1 [Gene - OMIM - HGNC]

Variant type:

single nucleotide variant

Cytogenetic location:

16p13.3

Genomic location:

Preferred name:

NM_002528.7(NTHL1):c.310C>A (p.His104Asn)

HGVS:

NC_000016.10:g.2046172G>T
NG_005895.1:g.1867G>T
NG_008412.1:g.6695C>A
NM_001318193.2:c.310C>A
NM_001318194.2:c.24+108C>A
NM_002528.7:c.310C>AMANE SELECT
NP_001305122.2:p.His104Asn
NP_002519.2:p.His104Asn
LRG_1366t1:c.310C>A
LRG_1366:g.6695C>A
LRG_1366p1:p.His104Asn
LRG_487:g.1867G>T
NC_000016.9:g.2096173G>T
NM_002528.5:c.334C>A

Protein change:

H104N

Molecular consequence:

NM_001318194.2:c.24+108C>A - intron variant - [Sequence Ontology: SO:0001627]
NM_001318193.2:c.310C>A - missense variant - [Sequence Ontology: SO:0001583]
NM_002528.7:c.310C>A - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:: Hereditary cancer-predisposing syndrome
Synonyms:: Neoplastic Syndromes, Hereditary; Tumor predisposition; Cancer predisposition; See all synonyms [MedGen]
Identifiers:: MONDO: MONDO:0015356; MeSH: D009386; MedGen: C0027672

Recent activity

Clear Turn Off Turn On

Nicolaides-Baraitser syndrome
Nicolaides-Baraitser syndrome

MedGen
C1303073[conceptid] (1)
MedGen

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV002605745	Ambry Genetics	criteria provided, single submitter (Ambry Variant Classification Scheme 2023)	Uncertain significance (Oct 30, 2021)	germline	clinical testing	Citation Link

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV002605745

Ambry Genetics

criteria provided, single submitter

(Ambry Variant Classification Scheme 2023)

Uncertain significance
(Oct 30, 2021)

germline

clinical testing

Citation Link

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Details of each submission

From Ambry Genetics, SCV002605745.2

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	not provided

Description

The p.H112N variant (also known as c.334C>A), located in coding exon 2 of the NTHL1 gene, results from a C to A substitution at nucleotide position 334. The histidine at codon 112 is replaced by asparagine, an amino acid with similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: May 1, 2024

ClinVar

Relating variation to medicine